InsiderTrades

Form 4 for GYRE GYRE THERAPEUTICS, INC.

Accepted 2026-06-22 16:02:41 ET · period of report 2026-06-09 · accession 0001140361-26-025950 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-06-22 16:02 2026-06-09+ GYRE Ye Weiguo COO M - OptEx $0.75 +11.0K 703.0K +2% +$8,250
DM 2026-06-22 16:02 2026-06-09+ GYRE Ye Weiguo COO S - Sale+OE $6.25 -11.0K 700.0K -2% -$68.7K
DM 2026-06-22 16:02 2026-06-09+ GYRE Ye Weiguo COO M - OptEx $0.00 -11.0K 827.7K -1% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-09 M A 3,000 $0.75 703,000 D — —
2 Common Common Stock 2026-06-09 S D 3,000 $6.15 700,000 D — —
3 Common Common Stock 2026-06-10 M A 5,000 $0.75 705,000 D — —
4 Common Common Stock 2026-06-10 S D 5,000 $6.24 700,000 D — — (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
5 Common Common Stock 2026-06-18 M A 3,000 $0.75 703,000 D — —
6 Common Common Stock 2026-06-18 S D 3,000 $6.35 700,000 D — —
7 Derivative Stock Option (Right to Buy) 2026-06-09 M D 3,000 $0.00 835,701 D $0.75 · — to 2030-10-31 3,000 Common Stock (F2) These options are vested in full.
8 Derivative Stock Option (Right to Buy) 2026-06-10 M D 5,000 $0.00 830,701 D $0.75 · — to 2030-10-31 5,000 Common Stock (F2) These options are vested in full.
9 Derivative Stock Option (Right to Buy) 2026-06-18 M D 3,000 $0.00 827,701 D $0.75 · — to 2030-10-31 3,000 Common Stock (F2) These options are vested in full.